Clinical trial NCT02198326: Single Rising Dose Tolerability Study of BIBN 4096 BS in Healthy Male and Female Volunteers
Official title: A Double-blind (Within Dose Groups), Placebo-controlled Single Rising Dose Tolerability Study (Parallel Groups) in Healthy Male and Female Volunteers After Intranasal Administration of BIBN 4096 BS (Dosage: 2.5 - 20 mg)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Healthy
Lead sponsor: Boehringer Ingelheim
Sponsor class: INDUSTRY
First posted: 2014-07-23
Enrollment: 32
Sex: ALL
Minimum age (years): 21
Maximum age (years): 50
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The objective of the present study is to obtain information about the safety, tolerability and pharmacokinetics of BIBN 4096 BS after single intranasal administration of increasing doses in healthy male and female volunteers


Eligibility criteria: Inclusion Criteria:

* Participants should be healthy males and females
* Age range from 21 to 50 years
* Within +- 20% of their normal weight (Broca-Index)
* All female volunteers must use a safe contraception (i.e. oral contraceptive, spiral; sterilized) and must have a negative pregnancy test
* In accordance with Good Clinical Practice (GCP) and local legislation each volunteer is supposed to give his written informed consent prior to admission to the study
* Each subject will have his medical history taken and will receive a complete medical examination (incl. blood pressure and pulse rate measurements) as well as a 12-lead Electrocardiogram (ECG) within 14 days before the first administration of the test substance
* Haematopoietic, hepatic and renal function test will be carried out in the laboratory
* The subjects will fast for 12 hours before collection of specimens for all laboratory evaluations

Exclusion Criteria:

* Volunteers will be excluded from the study if the results of the medical examination or laboratory tests (especially those which indicate liver malfunction) are judged by the clinical investigator to differ significantly from normal clinical values
* Volunteers with known gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
* Volunteers with diseases of the central nervous system (such as epilepsy) or with psychiatric disorders
* History of orthostatic hypotension, fainting spells or blackouts
* Chronic or relevant acute infections (especially common cold with rhinitis)
* History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
* Intake of a drug with a long half-life (\>= 24 hours) within ten half-lives of the respective drug before enrolment in the study
* Use of any other drugs which might influence the results of the trial during the week previous to the start of the study
* Participation in another study with an investigational drug within the last two months preceding this study
* Smoker (\> 10 cigarettes or 3 cigars or 3 pipes/day)
* Inability to refrain from smoking on study days
* Alcohol abuse (\> 40g/day)
* Drug abuse
* Blood donation ( \>= 100 ml) within the last 4 weeks
* Excessive physical activities (e.g. competitive sports) within the last week before the study
* Pregnant and/or lactating volunteers

Primary outcomes:
measure: Changes in nasal mucosa assessed by rhinoscopy
timeFrame: up to 2 hours after treatment
measure: Changes in nasal flow and resistance assessed by rhinomanometry
timeFrame: up to 2 hours after treatment
measure: Number of patients with adverse events
timeFrame: up to 24 days
Secondary outcomes:
measure: AUC (Area under the concentration-time curve of the analyte in plasma)
timeFrame: up to 12 hours after intranasal administration
measure: Cmax (Maximum measured concentration of the analyte in plasma)
timeFrame: up to 12 hours after intranasal administration
measure: tmax (Time from dosing to the maximum concentration of the analyte in plasma)
timeFrame: up to 12 hours after intranasal administration
measure: MRT (Mean residence time of the analyte in the body)
timeFrame: up to 12 hours after intranasal administration
measure: t½ (Terminal half-life of the analyte in plasma)
timeFrame: up to 12 hours after intranasal administration
measure: CL (systemic clearance)
timeFrame: up to 12 hours after intranasal administration
measure: Vd (Volume of distribution)
timeFrame: up to 12 hours after intranasal administration
Other outcomes:
Locations:
Study officials:
References: